News from 84th European Atherosclerosis Congress

Click here to invite colleagues
to join the Forum for FREE

4th Meeting of the PCSK9 Forum Editorial Board

News from 84th European Atherosclerosis Congress
29 May - 1 June, Innsbruck, Austria

Low LDL-C, PCSK9 and dementia risk?

An ongoing debate among the experts is whether the very low levels of LDL cholesterol with PCSK9 inhibitor treatment might be associated with neurocognitive events.

Read the report and watch the video »

TAUSSIG: Does adding evolocumab reduce cardiovascular events in homozygous FH?

Follow-up data from the TAUSSIG study suggest that adding evolocumab may reduce cardiovascular events due to the burden of high LDL cholesterol in homozygous FH.

Read the report and watch the video »

Changing the message on LDL cholesterol: Lifetime exposure is key

Until recently, the emphasis in clinical care has been to lower LDL cholesterol to the recommended goal, or even below these limits, as investigated with the PCSK9 inhibitors, but ensuring low LDL cholesterol for as long as possible may be better.

Read the report and watch the video »


New and updated edition of our popular therapeutic guide A second edition of the free introductory guide: PCSK9 Inhibition - New Therapies in Cardiovascular Risk Reduction is now available on the Forum’s website. This very popular book has been updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition. As you know, this downloadable e-book is freely available to all registered members of the Forum. Read online » Download now » Forward to colleagues »

		Questions & Answers Inhibition of PCSK9 offers the real possibility of improved management of high-risk patients. Read the full answer and other questions on the PCSK9 Forum »

Like us on Facebook

For the latest updates, PCSK9 news and analysis.

Hot topics, news and conference reports.

YouTube Channel

For videos, interviews and webcasts from leading experts.

Educational Partners
and Supporters